… with either a BRAF or MEK inhibitor. We believe that the combination of dabrafenib and …
metastatic melanoma with BRAF V600 mutations and other cancers with these mutations. …

… In conclusion, in our study involving previously untreated patients who had metastatic
melanoma with BRAF V600E or V600EK mutations, the combination of dabrafenib and trametinib, …

… BRAF-mutant metastatic melanoma by the US Food and Drug Administration (FDA) in 2013,
and most recently, their use in combination … inhibits mutant BRAF that constitutively activates …

… with the BRAF inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK
… approach in patients with BRAF-mutated metastatic melanoma. Both vemurafenib and …

… identified several regimens combining BRAF inhibitors and immunotherapy, all such regimens
were tested in single-arm trials. Therefore, all studies that included BRAF inhibitors and …

… Patients included in this study had BRAF V600 -mutant metastatic melanoma, had not received
prior immunotherapy and were treated with dabrafenib plus trametinib (CombiDT) as part …

… leading to the approval of BRAF/MEK inhibitors (BRAF/MEKi) for BRAF V600 -mutant
metastatic melanoma, and we explore the three major effectors of BRAF/MEK inhibitor resistance …

… trials combining inhibitors of both MEK and mutant BRAF kinase … BRAF inhibitor monotherapy.
In this review, we discuss existing clinical trial data on BRAF and MEK inhibitors together …

… Here, we report patients treated with combination therapy after disease progression with
BRAF inhibitor treatment administered before study enrollment (part B; n = 26) or after cross-…

… patients with metastatic melanoma with a BRAF Val600 mutation were randomly assigned
(1:1) by an interactive voice response system to receive either a combination of dabrafenib (…